Janux Therapeutics (NASDAQ:JANX) Issues Earnings Results, Misses Estimates By $0.10 EPS

Janux Therapeutics (NASDAQ:JANX) released its quarterly earnings data on Thursday. The company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10), FiscalAI reports. The company had revenue of $10.27 million during the quarter, compared to analyst estimates of $19.07 million.

Janux Therapeutics Price Performance

JANX stock traded down $0.25 on Friday, reaching $15.85. The company’s stock had a trading volume of 689,025 shares, compared to its average volume of 744,057. Janux Therapeutics has a 52 week low of $12.12 and a 52 week high of $35.34. The company has a market capitalization of $966.53 million, a P/E ratio of -9.66 and a beta of 2.50. The firm has a fifty day moving average of $15.04 and a two-hundred day moving average of $14.44.

Analysts Set New Price Targets

Several equities research analysts have weighed in on JANX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Janux Therapeutics in a research report on Monday, July 20th. Wedbush reduced their price target on shares of Janux Therapeutics from $45.00 to $36.00 and set an “outperform” rating for the company in a report on Friday, May 8th. UBS Group lowered shares of Janux Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $57.00 to $15.00 in a research report on Wednesday, April 15th. Barclays cut shares of Janux Therapeutics from an “overweight” rating to an “underweight” rating and dropped their price objective for the stock from $29.00 to $14.00 in a report on Monday, April 20th. Finally, Evercore set a $22.00 price objective on shares of Janux Therapeutics in a research report on Monday, May 11th. Nine equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Janux Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $37.58.

Insider Buying and Selling at Janux Therapeutics

In other news, insider Janeen Noel Doyle sold 4,059 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $14.03, for a total value of $56,947.77. Following the completion of the transaction, the insider owned 75,941 shares of the company’s stock, valued at approximately $1,065,452.23. This represents a 5.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, VP Maria Dobek sold 2,038 shares of the firm’s stock in a transaction on Monday, May 11th. The shares were sold at an average price of $14.17, for a total value of $28,878.46. Following the transaction, the vice president directly owned 32,270 shares in the company, valued at $457,265.90. This trade represents a 5.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 7.90% of the stock is owned by insiders.

Hedge Funds Weigh In On Janux Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of JANX. Engineers Gate Manager LP increased its position in shares of Janux Therapeutics by 47.5% during the 4th quarter. Engineers Gate Manager LP now owns 13,147 shares of the company’s stock valued at $181,000 after purchasing an additional 4,231 shares during the period. Entropy Technologies LP acquired a new stake in shares of Janux Therapeutics in the fourth quarter valued at $222,000. Aristides Capital LLC acquired a new stake in shares of Janux Therapeutics in the fourth quarter valued at $181,000. Jain Global LLC bought a new position in Janux Therapeutics during the third quarter valued at about $241,000. Finally, Inceptionr LLC bought a new position in Janux Therapeutics during the third quarter valued at about $245,000. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.